Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”

Laurens A. van Kleef; Robert J. de Knegt

doi:10.1002/hep4.2006

Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”

Laurens A. van Kleef, Robert J. de Knegt^*

^*Corresponding author for this work

Gastroenterology & Hepatology

Research output: Contribution to journal › Article › Academic › peer-review

5 Downloads (Pure)

Original language	English
Pages (from-to)	2605-2606
Number of pages	2
Journal	Hepatology Communications
Volume	6
Issue number	9
Early online date	20 May 2022
DOIs	https://doi.org/10.1002/hep4.2006
Publication status	Published - Sep 2022

Bibliographical note

Funding Information:
Supported by the Foundation for Liver and Gastrointestinal Research, Rotterdam, the Netherlands

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hep4.2006Licence: CC BY

Reply to “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”Final published version, 159 KBLicence: CC BY

Cite this

@article{cd351d048ef140a6975f556689876ba0,

title = "Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”",

author = "{van Kleef}, {Laurens A.} and {de Knegt}, {Robert J.}",

note = "Funding Information: Supported by the Foundation for Liver and Gastrointestinal Research, Rotterdam, the Netherlands",

year = "2022",

month = sep,

doi = "10.1002/hep4.2006",

language = "English",

volume = "6",

pages = "2605--2606",

number = "9",

}

TY - JOUR

T1 - Reply to

T2 - “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”

AU - van Kleef, Laurens A.

AU - de Knegt, Robert J.

N1 - Funding Information: Supported by the Foundation for Liver and Gastrointestinal Research, Rotterdam, the Netherlands

PY - 2022/9

Y1 - 2022/9

UR - http://www.scopus.com/inward/record.url?scp=85130271768&partnerID=8YFLogxK

U2 - 10.1002/hep4.2006

DO - 10.1002/hep4.2006

M3 - Article

C2 - 35593157

AN - SCOPUS:85130271768

VL - 6

SP - 2605

EP - 2606

IS - 9

ER -

Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this